Get the Stockscreener App
26.19
1.17%
-0.31
After Hours:
26.71
0.52
+1.99%
Rapport Therapeutics Inc stock is traded at $26.19, with a volume of 631.43K.
It is down -1.17% in the last 24 hours and up +10.23% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$26.50
Open:
$26.37
24h Volume:
631.43K
Relative Volume:
0.89
Market Cap:
$955.88M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-5.59%
1M Performance:
+10.23%
6M Performance:
+182.83%
1Y Performance:
+18.78%
1-Day Range:
$25.95
$27.30
1-Week Range:
$25.79
$27.72
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
26.19 | 1.22B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Statistical indicators supporting Rapport Therapeutics Inc.’s strengthSell Signal & AI Based Trade Execution Alerts - newser.com
Analyzing net buyer seller activity in Rapport Therapeutics Inc.Trade Analysis Summary & Safe Entry Trade Reports - newser.com
Can volume confirm reversal in Rapport Therapeutics Inc.2025 Key Highlights & Risk Controlled Stock Alerts - newser.com
Has Rapport Therapeutics Inc. found a price floor2025 Trading Recap & Low Risk High Reward Ideas - newser.com
Multi factor analysis applied to Rapport Therapeutics Inc.Weekly Gains Report & Growth Focused Entry Point Reports - newser.com
Rapport Therapeutics Inc. stock chart pattern explainedMarket Risk Analysis & Weekly High Return Opportunities - newser.com
How to recover losses in Rapport Therapeutics Inc. stock2025 Volume Leaders & AI Powered Trade Plan Recommendations - newser.com
Published on: 2025-10-12 22:23:14 - newser.com
Volatility clustering patterns for Rapport Therapeutics Inc.Risk Management & Long Hold Capital Preservation Tips - newser.com
Identifying reversal signals in Rapport Therapeutics Inc.Weekly Trading Summary & Risk Controlled Stock Pick Alerts - newser.com
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Key metrics from Rapport Therapeutics Inc.’s quarterly dataJuly 2025 Levels & Risk Controlled Daily Plans - newser.com
Smart tools for monitoring Rapport Therapeutics Inc.’s price actionJuly 2025 Decliners & Growth Oriented Trading Recommendations - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Applying big data sentiment scoring on Rapport Therapeutics Inc.Quarterly Profit Summary & Weekly Watchlist of Top Performers - newser.com
Should you hold or exit Rapport Therapeutics Inc. nowMarket Trend Review & Real-Time Volume Analysis Alerts - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 2.3%What's Next? - MarketBeat
What analysts say about Rapport Therapeutics Inc stockStock Buy Signals & Invest Now – Opportunity Window Closing - earlytimes.in
Full technical analysis of Rapport Therapeutics Inc. stockJuly 2025 Levels & Verified Chart Pattern Trade Signals - newser.com
Applying Elliott Wave Theory to Rapport Therapeutics Inc.Weekly Volume Report & Weekly Chart Analysis and Guides - newser.com
Momentum divergence signals in Rapport Therapeutics Inc. chartJuly 2025 Gainers & Weekly High Conviction Trade Ideas - newser.com
How institutional ownership impacts Rapport Therapeutics Inc. stockWeekly Trend Recap & Capital Efficient Trade Techniques - newser.com
Using data filters to optimize entry into Rapport Therapeutics Inc.July 2025 Closing Moves & Target Return Focused Stock Picks - newser.com
Why Rapport Therapeutics Inc. stock could be next big winner2025 Growth vs Value & AI Powered Market Entry Strategies - newser.com
Is Rapport Therapeutics Inc. stock recession proofMarket Risk Report & Verified Short-Term Plans - newser.com
Rapport Therapeutics (NASDAQ:RAPP) Shares Down 7.3%Here's What Happened - MarketBeat
Why Rapport Therapeutics (RAPP) Is Up 6.3% After Positive Phase 2a Epilepsy Drug Results and Analyst Optimism - Yahoo Finance
Rapport Therapeutics (NASDAQ:RAPP) Shares Gap DownTime to Sell? - MarketBeat
Rapport Therapeutics (NASDAQ:RAPP) Trading 4.3% HigherShould You Buy? - MarketBeat
JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success - Insider Monkey
11 Best Fast Money Stocks to Buy Now - Insider Monkey
How Harsha Engineers International Limited Performs During Inflation Historical OverviewVolume Profile Analysis & Free Short-Term Trading Strategies - earlytimes.in
What drives Bitdeer Technologies Group stock priceSmall Cap Stock Opportunities & High Yield Investment Portfolio - Early Times
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Rapport Therapeutics Inc Stock (RAPP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ceesay Abraham | Chief Executive Officer |
Sep 17 '25 |
Sale |
26.32 |
35,585 |
936,472 |
46,144 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):